Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arun A Azad

Showing results (71-80 of 140) with videos related to

Pageof 14
Sort By:
Journal of Geriatric Oncology|September 8, 2023
Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohortMichael Fernando, Angelyn Anton, Andrew Weickhardt, et al.
BJU International|March 8, 2021
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, et al.
Frontiers in Medicine|December 5, 2022
AlphaBet: Combination of Radium-223 and [<sup>17</sup> <sup>7</sup>Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)Louise Kostos, James P Buteau, Theresa Yeung, et al.
European Urology|October 30, 2025
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [<sup>177</sup>Lu]Lu-PSMA-617Heidi Fettke, Louise Kostos, Maria Docanto, et al.
European Urology Oncology|December 10, 2023
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc AnalysisFrancisco Gomez-Veiga, Russell Z Szmulewitz, Jeffrey Holzbeierlein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 22, 2026
Thrombotic Microangiopathy in Patients Treated with <sup>177</sup>Lu-PSMA Combination TherapiesJoanna C Chan, Mitchell T Carroll, Nadia Hitchen, et al.
Future Oncology (London, England)|June 30, 2025
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language reviewPaul E Dato, Jose De La Cerda, Andrew J Armstrong, et al.
Future Oncology (London, England)|May 11, 2026
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocolsNeal D Shore, Karim Fizazi, Michael Thomas Schweizer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 18, 2025
Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [<sup>68</sup>Ga]PSMA-11 or [<sup>18</sup>F]DCFPyL, [<sup>18</sup>F]FDG, and [<sup>177</sup>Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus NetworkPrice Jackson, James P Buteau, Lachlan McIntosh, et al.
European Urology|February 6, 2018
Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate CancerSarah Q To, Edmond M Kwan, Heidi C Fettke, et al.
Pageof 14

Showing results (71-80 of 140) with videos related to

Sort By:
Pageof 14
Journal of Geriatric Oncology|September 8, 2023
Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohortMichael Fernando, Angelyn Anton, Andrew Weickhardt, et al.
BJU International|March 8, 2021
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, et al.
Frontiers in Medicine|December 5, 2022
AlphaBet: Combination of Radium-223 and [<sup>17</sup> <sup>7</sup>Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)Louise Kostos, James P Buteau, Theresa Yeung, et al.
European Urology|October 30, 2025
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [<sup>177</sup>Lu]Lu-PSMA-617Heidi Fettke, Louise Kostos, Maria Docanto, et al.
European Urology Oncology|December 10, 2023
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc AnalysisFrancisco Gomez-Veiga, Russell Z Szmulewitz, Jeffrey Holzbeierlein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 22, 2026
Thrombotic Microangiopathy in Patients Treated with <sup>177</sup>Lu-PSMA Combination TherapiesJoanna C Chan, Mitchell T Carroll, Nadia Hitchen, et al.
Future Oncology (London, England)|June 30, 2025
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language reviewPaul E Dato, Jose De La Cerda, Andrew J Armstrong, et al.
Future Oncology (London, England)|May 11, 2026
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocolsNeal D Shore, Karim Fizazi, Michael Thomas Schweizer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 18, 2025
Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [<sup>68</sup>Ga]PSMA-11 or [<sup>18</sup>F]DCFPyL, [<sup>18</sup>F]FDG, and [<sup>177</sup>Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus NetworkPrice Jackson, James P Buteau, Lachlan McIntosh, et al.
European Urology|February 6, 2018
Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate CancerSarah Q To, Edmond M Kwan, Heidi C Fettke, et al.
Pageof 14